Private company

REGENERX BIOPHARMACEUTICALS INC

REGENERX BIOPHARMACEUTICALS INC is an American pharmaceutical preparations company, incorporated in Delaware.¹ It is headquartered in Rockville, Maryland.¹

Last updated Oct 20, 2026.

Overview

IndustryPharmaceutical Preparations¹
HeadquartersRockville, Maryland¹
Incorporated inDE²
Business address15245 Shady Grove Road, Suite 470, Rockville, Md 20850²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-1826.4%Operating margin³

-2250.4%Net margin³

0.0%Revenue growth, 2022³

Where the money goes

Where each dollar of revenue went, fiscal 2022

Interest

Interest100¢$325.6K

Out of $76.8K in revenue.³ The company lost money this year.

Financial statements

Revenue⁴⁵⁶⁷⁸³$76.8K in 2022−18% since 2016

Operating income⁴⁵⁶⁷⁸³-$1.4M in 2022−16% since 2016

Net income⁴⁵⁶⁷⁸³-$1.7M in 2022

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Revenue	$93.3K⁴	$56.7K⁵	$69.7K⁶	$76.8K⁷	$76.8K⁸	$76.8K³	$76.8K³
Research and development	$237.3K⁴	$143.9K⁵	$81.0K⁶	$65.1K⁷	$4.9K⁸	$6.6K³	$0³
Operating expenses						$1.4M³	$1.5M³
Operating income	-$1.7M⁴	-$1.4M⁵	-$1.3M⁶	-$1.3M⁷	-$1.3M⁸	-$1.3M³	-$1.4M³
Interest	$173.4K⁴	$170.9K⁵	$87.3K⁶	$153.4K⁷	$232.6K⁸	$324.9K³	$325.6K³
Income before tax						-$1.6M³	-$1.7M³
Income tax	$0⁴	$98.6K⁵	$0⁶	$0⁷	$0⁸	$0³	$0³
Net income	$229.1K⁴	$286.5K⁵	-$2.0M⁶	-$1.4M⁷	-$1.5M⁸	-$1.6M³	-$1.7M³
Earnings per share	$0.00⁴	$0.00⁵	-$0.02⁶	-$0.01⁷	-$0.01⁸	-$0.01³	-$0.01³
Earnings per share (diluted)	$0.00⁴	$0.00⁵	-$0.02⁶	-$0.01⁷	-$0.01⁸	-$0.01³	-$0.01³
Shares (weighted, basic)						138.6M shares³	143.5M shares³
Shares (weighted, diluted)						138.6M shares³	143.5M shares³

Total assets⁴⁵⁶⁷⁸³$382.2K in 2022−56% since 2016

Total liabilities⁴⁵⁶⁷⁸³$3.8M in 2022−45% since 2016

Shareholders’ equity⁵⁶⁷⁸³-$3.4M in 2022−43% since 2016

Cash⁵⁶⁷⁸³$290.9K in 2022−62% since 2016

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Cash	$769.5K⁵	$181.7K⁵	$237.3K⁶	$639.9K⁷	$427.9K⁸	$1.2M³	$290.9K³
Current assets	$849.4K⁴	$217.2K⁵	$273.9K⁶	$681.6K⁷	$477.8K⁸	$1.3M³	$306.9K³
Total assets	$862.4K⁴	$227.1K⁵	$281.0K⁶	$711.8K⁷	$551.8K⁸	$1.3M³	$382.2K³
Accounts payable						$63.6K³	$63.8K³
Current liabilities	$659.8K⁴	$2.2M⁵	$315.0K⁶	$242.5K⁷	$399.6K⁸	$429.9K³	$553.7K³
Total liabilities	$6.9M⁴	$4.3M⁵	$2.5M⁶	$3.1M⁷	$3.4M⁸	$3.5M³	$3.8M³
Retained earnings						-$110.5M³	-$112.2M³
Shareholders’ equity	-$6.1M⁵	-$4.1M⁶	-$2.2M⁷	-$2.3M⁸	-$2.8M³	-$2.2M³	-$3.4M³
Shares outstanding	106.8M shares⁴	109.8M shares⁵	128.4M shares⁶	131.5M shares⁷	133.4M shares⁸	143.5M shares³	143.5M shares³

Cash from operations⁴⁵⁶⁷⁸³-$940.7K in 2022−12% since 2016

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Cash from operations	-$1.1M⁴	-$663.1K⁵	-$888.3K⁶	-$1.1M⁷	-$1.0M⁸	-$990.3K³	-$940.7K³
Stock-based compensation						$397.8K³	$511.9K³
Capital spending	$0¹²
Free cash flow	-$1.1M
Cash from financing						$1.8M³	$0³

Compare REGENERX BIOPHARMACEUTICALS INC with another company

Corporate structure

REGENERX BIOPHARMACEUTICALS INC sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of REGENERX BIOPHARMACEUTICALS INC

Essetifin SPA Filed SC 13D/A on REGENERX BIOPHARMACEUTICALS INC, latest Jul 6, 2023

REGENERX BIOPHARMACEUTICALS INC Rockville, Maryland

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What REGENERX BIOPHARMACEUTICALS INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Item	Latest	A year before	Change
Operating-lease assets (leased space)	$69.5K³ Dec 31, 2022	$27.7K³ Dec 31, 2021	+151.2%

Investments

Item	Latest	A year before	Change
Cash and cash equivalents	$290.9K³ Dec 31, 2022	$1.2M³ Dec 31, 2021	−76.4%

Leadership

Who has led REGENERX BIOPHARMACEUTICALS INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Chief financial officer

2010201520202025

Chief executive officerAllan L. Goldstein Jan 28, 2008 to Jan 28, 2008¹³
Chief executive officerJ. J. Finkelstein May 30, 2006 to May 19, 2022¹⁴
PresidentAllan L. Goldstein Jan 28, 2008 to Jan 28, 2008¹³
PresidentJ. J. Finkelstein May 30, 2006 to May 19, 2022¹⁴
Chief financial officerDane R. Saglio Apr 25, 2014 to Apr 25, 2014¹⁵
Chief financial officerC. Neil Lyons Mar 19, 2007 to Jul 16, 2010¹⁶

Board members and other officers (10)

Chief ScientificAllan L. Goldstein Jan 9, 2014 to Jan 9, 2014¹⁷
VP of Clinical and Reg AffairsDavid Crockford Apr 10, 2007 to Apr 5, 2012¹⁸
Board memberAlessandro Noseda May 17, 2019 to May 19, 2022¹⁹
Board memberR. Don Elsey Sep 3, 2010 to May 19, 2022²⁰
Board memberAllan L. Goldstein Mar 19, 2007 to May 19, 2022²¹
Board memberJoseph C. McNay Mar 19, 2007 to May 19, 2022²²
Board memberRichard J. Hindin Mar 19, 2007 to Oct 14, 2009²³
Board memberMauro Bove Apr 12, 2007 to May 19, 2022²⁴
Board memberL. Thompson Bowles Mar 10, 2006 to Apr 1, 2014²⁵
Board memberJ. J. Finkelstein May 30, 2006 to May 19, 2022¹⁴

Former names

ALPHA 1 BIOMEDICALS INCDec 28, 1995 to May 11, 2001²
ALPHA 1 BIOMEDICALS INC /DE/Mar 9, 1994 to Feb 7, 1995²

Timeline

Aug 7, 20238-K Shareholder vote; Other events²⁶
Jul 10, 20238-K Entered a material agreement; Unregistered sale of shares; Other events²⁷
Jun 21, 20238-K Entered a material agreement; Unregistered sale of shares²⁸
Nov 15, 20218-K Bylaws or fiscal year changed; Shareholder vote; Other events²⁹
Jan 28, 2008New chief executive Allan L. Goldstein becomes CEO¹³
May 30, 2006New chief executive J. J. Finkelstein becomes CEO¹⁴

Filings

28 filings to the SEC since October 2021: 2 annual reports, 5 quarterly reports, 4 major events, 8 insider forms, 1 large holders, 8 other. The latest 20:

Aug 14, 202315-12G EDGAR
Aug 7, 20238-K EDGAR
Jul 11, 2023DEF 14A EDGAR
Jul 10, 20238-K EDGAR
Jul 6, 2023SC 13D/A AMENDMENT NO. 26 TO SCHEDULE 13D EDGAR
Jul 6, 20234 OWNERSHIP DOCUMENT EDGAR
Jun 26, 2023PRE 14A EDGAR
Jun 21, 20238-K EDGAR
May 15, 202310-Q EDGAR
Apr 11, 202310-K EDGAR
Apr 3, 2023NT 10-K EDGAR
Nov 14, 202210-Q EDGAR
Aug 12, 202210-Q EDGAR
May 19, 20224 EDGAR
May 19, 20224 EDGAR
May 19, 20224 EDGAR
May 19, 20224 EDGAR
May 19, 20224 EDGAR
May 19, 20224 EDGAR
May 16, 202210-Q EDGAR

The 28 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Essetifin SPASC 13D/A, 1 filing Jul 6, 2023³⁰

SEC filer profile

How REGENERX BIOPHARMACEUTICALS INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARREGENERX BIOPHARMACEUTICALS INC¹
CIK0000707511
Employer ID (EIN)52-1253406¹
Filer statusNon-accelerated filer<br>smaller reporting company¹
Incorporated inDelaware¹
Fiscal year endsDecember 31¹
Industry code (SIC)2834 Pharmaceutical Preparations¹
Business address15245 Shady Grove Road, Suite 470, Rockville, MD 20850¹
Phone301-208-9191¹
Shares outstanding143,549,735 as of May 11, 2023¹¹
Public float$16.0M as of Feb 25, 2023³
On EDGAR sinceFeb 14, 1994¹
Filings760 in all: 4 (233), 8-K (103), SC 13D/A (97), 10-Q (61), 424B3 (32), DEF 14A (20), 10QSB (18), 10-K (17)¹
All 55 form types
3 (16), 5 (11), CORRESP (8), D (8), EFFECT (8), SC 13D (8), UPLOAD (8), 10KSB (7), 4/A (7), S-1/A (7), NT 10-K (6), REGDEX (6), ARS (5), CT ORDER (5), DEFA14A (5), PRE 14A (5), S-1 (5), S-3 (4), 10-K405 (3), 10-Q/A (3), NT 10-Q (3), S-3/A (3), S-8 (3), SB-2/A (3), 10-K/A (2), 10-K405/A (2), 15-12G (2), 3/A (2), 424B5 (2), 8-K/A (2), PRER14A (2), SC 13G (2), SC 13G/A (2), 10KSB/A (1), 10QSB/A (1), 25-NSE (1), 424B2 (1), 424B4 (1), 424B7 (1), 8-A12B (1), 8-A12G (1), DEF 14C (1), DEFR14A (1), DEL AM (1), POS AM (1), PRE 14C (1), SB-2 (1)
Latest filingsAnnual report (10-K) Apr 11, 2023
Quarterly report (10-Q) May 15, 2023
Proxy statement (DEF 14A) Jul 11, 2023
Latest 8-K (8-K) Aug 7, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARREGENERX BIOPHARMACEUTICALS INC filings on SEC EDGAR
2
SEC EDGARREGENERX BIOPHARMACEUTICALS INC filings on SEC EDGAR
3
SEC EDGARREGENERX BIOPHARMACEUTICALS INC 10-K for fiscal 2022
4
SEC EDGARREGENERX BIOPHARMACEUTICALS INC 10-K for fiscal 2016
5
SEC EDGARREGENERX BIOPHARMACEUTICALS INC 10-K for fiscal 2017
6
SEC EDGARREGENERX BIOPHARMACEUTICALS INC 10-K for fiscal 2018
7
SEC EDGARREGENERX BIOPHARMACEUTICALS INC 10-K for fiscal 2019
8
SEC EDGARREGENERX BIOPHARMACEUTICALS INC 10-K for fiscal 2020
9
SEC EDGARREGENERX BIOPHARMACEUTICALS INC 10-Q for fiscal 2022
10
SEC EDGARREGENERX BIOPHARMACEUTICALS INC 10-Q for fiscal 2022
11
SEC EDGARREGENERX BIOPHARMACEUTICALS INC 10-Q for fiscal 2023
12
SEC EDGARREGENERX BIOPHARMACEUTICALS INC 10-K for fiscal 2016
13
SEC EDGARAllan L. Goldstein, Chief executive officer
14
SEC EDGARJ. J. Finkelstein, Chief executive officer
15
SEC EDGARDane R. Saglio, Chief financial officer
16
SEC EDGARC. Neil Lyons, Chief financial officer
17
SEC EDGARAllan L. Goldstein, Chief Scientific
18
SEC EDGARDavid Crockford, VP of Clinical and Reg Affairs
19
SEC EDGARAlessandro Noseda, Board member
20
SEC EDGARR. Don Elsey, Board member
21
SEC EDGARAllan L. Goldstein, Board member
22
SEC EDGARJoseph C. McNay, Board member
23
SEC EDGARRichard J. Hindin, Board member
24
SEC EDGARMauro Bove, Board member
25
SEC EDGARL. Thompson Bowles, Board member
26
SEC EDGARShareholder vote; Other events
27
SEC EDGAREntered a material agreement; Unregistered sale of shares; Other events
28
SEC EDGAREntered a material agreement; Unregistered sale of shares
29
SEC EDGARBylaws or fiscal year changed; Shareholder vote; Other events
30
SEC EDGAREssetifin SPA SC 13D/A on REGENERX BIOPHARMACEUTICALS INC